Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Absorption, Metabolism, and Excretion of [14C]MK-0767 (2-Methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in Humans

Christopher J. Kochansky, Ronda K. Rippley, Kerri X. Yan, Hengchang Song, Michael A. Wallace, Dennis Dean, Allen N. Jones, Kenneth Lasseter, Jules Schwartz, Stella H. Vincent, Ronald B. Franklin and John Wagner
Drug Metabolism and Disposition September 2006, 34 (9) 1457-1461; DOI: https://doi.org/10.1124/dmd.106.010231
Christopher J. Kochansky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronda K. Rippley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerri X. Yan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hengchang Song
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael A. Wallace
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis Dean
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allen N. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth Lasseter
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jules Schwartz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stella H. Vincent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald B. Franklin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Wagner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

MK-0767 (KRP-297; 2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) is a thiazolidinedione (TZD)-containing dual agonist of the peroxisome proliferator-activated receptors α and γ that has been studied as a potential treatment for patients with type 2 diabetes. The metabolism and excretion of [14C]MK-0767 were evaluated in six human volunteers after a 5-mg (200 μCi) oral dose. Excretion of 14C radioactivity was found to be nearly equal into the urine (∼50%) and feces (∼40%). Elimination of [14C]MK-0767 was primarily by metabolism, with minimal excretion of parent compound into the urine (<0.5% of dose) and feces (∼14% of the dose). [14C]MK-0767 was the major circulating compound-related entity (>96% of radioactivity) through 48 h postdose. It was also found that ∼91% of the total radioactivity area under the curve was due to intact MK-0767. Several minor metabolites were detected in plasma (<1% of radioactivity, each), formed by cleavage of the TZD ring and subsequent S-methylation and oxidation. All the metabolites excreted into urine were formed by TZD cleavage, whereas the major metabolite in feces was the O-demethylated derivative of MK-0767.

Footnotes

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.106.010231.

  • ABBREVIATIONS: MK-0767, (±)-5-[2,4-dioxothiazol-5-yl)methyl]-2-methoxy-N-[4-trifluoromethyl] benzamide; HPLC, high-performance liquid chromatography; LC-MS/MS, liquid chromatography-tandem mass spectrometry; AUC, area under the curve; PPAR, peroxisome proliferator-activated receptor; TZD, thiazolidinedione.

    • Received March 22, 2006.
    • Accepted May 31, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 34 (9)
Drug Metabolism and Disposition
Vol. 34, Issue 9
1 Sep 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Absorption, Metabolism, and Excretion of [14C]MK-0767 (2-Methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in Humans
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Absorption, Metabolism, and Excretion of [14C]MK-0767 (2-Methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in Humans

Christopher J. Kochansky, Ronda K. Rippley, Kerri X. Yan, Hengchang Song, Michael A. Wallace, Dennis Dean, Allen N. Jones, Kenneth Lasseter, Jules Schwartz, Stella H. Vincent, Ronald B. Franklin and John Wagner
Drug Metabolism and Disposition September 1, 2006, 34 (9) 1457-1461; DOI: https://doi.org/10.1124/dmd.106.010231

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Absorption, Metabolism, and Excretion of [14C]MK-0767 (2-Methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in Humans

Christopher J. Kochansky, Ronda K. Rippley, Kerri X. Yan, Hengchang Song, Michael A. Wallace, Dennis Dean, Allen N. Jones, Kenneth Lasseter, Jules Schwartz, Stella H. Vincent, Ronald B. Franklin and John Wagner
Drug Metabolism and Disposition September 1, 2006, 34 (9) 1457-1461; DOI: https://doi.org/10.1124/dmd.106.010231
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Oral PBPK Modeling of Vismodegib
  • Transporter-enzyme interplay in PK of PF-06835919
  • PBPK Model of Vit D3 and Metabolites
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics